News

SLS-004 Lowered Alpha-synuclein Levels in Mice

SLS-004, Seelos Therapeutics’ experimental epigenetic editing therapy for Parkinson’s disease, effectively reduced the production of alpha-synuclein — the protein that accumulates in toxic clumps in Parkinson’s — in the brains of healthy mice. Epigenetic modifications refer to the addition of chemical marks to DNA by a group of specialized…

Probiotics May Reduce Some Signs of Gut Inflammation

Probiotic supplements could prove a useful add-on therapy for people with Parkinson’s disease, a recent study suggests. The study, “Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson’s disease,” was published in the International Journal…

Rodent Study Reveals Anti-inflammatory Effects of Mirapex

Mirapex (pramipexole), an approved medication to treat motor symptoms in Parkinson’s disease, reduced levels of immune proteins in the brain that are associated with inflammation, a rat model study reveals. The study, “Effect of Pramipexole on Inflammatory Response in Central Nervous System of Parkinson’s Disease…

Parkinson’s Neurons Form Atypical Networks

Parkinson’s disease brain cells form abnormal networks that might predispose the cells toward damage, according to new research done using cells in laboratory conditions. “These discoveries open the door to early diagnosis, which would allow us to carry out a premature intervention that would slow down neuronal death, and…

Voice-assisted Devices May Help Patients to Speak More Clearly

People with Parkinson’s disease who use voice-assisted technologies (VATs) — software programs that respond to voice commands, like Amazon’s Alexa or Apple’s Siri — may find that they help to improve their speech by prodding them to practice speaking more clearly, a study based on an online patient survey…

2 Nanoparticles Show Potential to Prevent Amyloid Clumping

Nb10 and TiNb9, two nanoparticles of a particular chemical element, effectively reduce the formation of toxic amyloid fibrils — a hallmark of Parkinson’s and Alzheimer’s diseases, a lab dish study showed. Particularly, these nanoparticles suppressed the assembly of toxic clumps of S100A9, a pro-inflammatory molecule that is central to…

Alector, GSK Partner to Develop 2 Therapies for Dementia

Alector and GlaxoSmithKline (GSK) will collaborate in developing and commercializing two therapies aimed at treating an uncommon type of dementia that can cause problems with behavior and language. Both investigational therapies — AL001 and AL101 — can be used across a range of neurodegenerative disorders, including Parkinson’s,…

COVID-19 Lockdown Increased Impulse Control Disorders in Spain

Impulse control disorders (ICDs) among people with Parkinson’s disease were significantly more common and more severe after a COVID-19-related lockdown than before the pandemic, according to a small study in Spain. Also, patients who developed ICDs in the post-lockdown period were younger, developed Parkinson’s at a younger age, or had more…